Breast Cancer Patient-Derived Scaffolds Can Expose Unique Individual Cancer Progressing Properties of the Cancer Microenvironment Associated with Clinical CharacteristicsShow others and affiliations
2022 (English)In: Cancers, ISSN 2072-6694, Vol. 14, no 9, article id 2172Article in journal (Refereed) Published
Abstract [en]
Breast cancer is a heterogeneous disease in terms of cellular and structural composition, and besides acquired aggressive properties in the cancer cell population, the surrounding tumor microenvironment can affect disease progression and clinical behaviours. To specifically decode the clinical relevance of the cancer promoting effects of individual tumor microenvironments, we performed a comprehensive test of 110 breast cancer samples using a recently established in vivo-like 3D cell culture platform based on patient-derived scaffolds (PDSs). Cell-free PDSs were recellularized with three breast cancer cell lines and adaptation to the different patient-based microenvironments was monitored by quantitative PCR. Substantial variability in gene expression between individual PDS cultures from different patients was observed, as well as between different cell lines. Interestingly, specific gene expression changes in the PDS cultures were significantly linked to prognostic features and clinical information from the original cancer. This link was even more pronounced when ERα-status of cell lines and PDSs matched. The results support that PDSs cultures, including a cancer cell line of relevant origin, can monitor the activity of the tumor microenvironment and reveal unique information about the malignancy-inducing properties of the individual cancer niche and serve as a future complementary diagnostic tool for breast cancer. © 2022 by the authors.
Place, publisher, year, edition, pages
MDPI , 2022. Vol. 14, no 9, article id 2172
Keywords [en]
breast cancer, cancer stem cells, patient-derived scaffolds, translational research, tumor microenvironment
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:ri:diva-59228DOI: 10.3390/cancers14092172Scopus ID: 2-s2.0-85128735643OAI: oai:DiVA.org:ri-59228DiVA, id: diva2:1667347
Note
Funding details: 2017-03737; Funding details: 965065, 965580; Funding details: Cancerfonden, 19-0306, 19-0317; Funding details: Vetenskapsrådet, VR, 2019-01273, 2020-04141; Funding text 1: This research was funded by V?stra G?taland Regional Council Sweden, Swedish Research Council (2019-01273 and 2020-04141), Sweden?s Innovation Agency Vinnova (2017-03737), Swedish Cancer Society (19-0317 and 19-0306) and the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (965580 and 965065).; Funding text 2: Funding: This research was funded by Västra Götaland Regional Council Sweden, Swedish Research Council (2019-01273 and 2020-04141), Sweden’s Innovation Agency Vinnova (2017-03737), Swedish Cancer Society (19-0317 and 19-0306) and the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (965580 and 965065).
2022-06-102022-06-102023-05-22Bibliographically approved